Journal article
Phenylephrine prodrug. Report of clinical trials
Ophthalmology (Rochester, Minn.), Vol.98(2), pp.222-226
02/1991
DOI: 10.1016/S0161-6420(91)32313-3
PMID: 2008281
Abstract
The authors evaluated the mydriatic effect of phenylephrine oxazolidine prodrug, a lipophilic sympathomimetic that undergoes hydrolysis to phenylephrine as it passes through the cornea and aqueous humor. Double-masked clinical trials were performed randomizing 66 healthy subjects to receive either the silicone vehicle as a placebo, 10% viscous phenylephrine hydrochloride (HCl), or prodrug in 0.25%, 0.50%, or 1.0% concentrations. A mean horizontal pupillary diameter of 8.8 mm was achieved in 30 minutes in those receiving 1% prodrug versus 6.5 mm obtained at 30 minutes with 10% viscous phenylephrine HCl. Statistically, this difference was highly significant at P less than or equal to 0.0001. There were minimal systemic or ocular adverse effects from any preparation.
Details
- Title: Subtitle
- Phenylephrine prodrug. Report of clinical trials
- Creators
- M J Miller-Meeks - Department of Ophthalmology, University of Iowa, Iowa CityT A FarrellP M MundenJ C FolkC RaoR D Schoenwald
- Resource Type
- Journal article
- Publication Details
- Ophthalmology (Rochester, Minn.), Vol.98(2), pp.222-226
- Publisher
- United States
- DOI
- 10.1016/S0161-6420(91)32313-3
- PMID
- 2008281
- ISSN
- 0161-6420
- eISSN
- 1549-4713
- Language
- English
- Date published
- 02/1991
- Academic Unit
- Pharmacy; Ophthalmology and Visual Sciences
- Record Identifier
- 9983980045402771
Metrics
10 Record Views